RK‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aberrant activation of Wnt/β‐catenin signaling causes tumorigenesis and promotes the proliferation of colorectal cancer cells. Porcupine inhibitors, which block secretion of Wnt ligands, may have only limited clinical impact for the treatment of colorectal cancer, because most colorectal cancer is caused by loss‐of‐function mutations of the tumor suppressor adenomatous polyposis coli (APC) downstream of Wnt ligands. Tankyrase poly(ADP‐ribosyl)ates (PAR ylates) Axin, a negative regulator of β‐catenin. This post‐translational modification causes ubiquitin‐dependent degradation of Axin, resulting in β‐catenin accumulation. Tankyrase inhibitors downregulate β‐catenin and suppress the growth of APC‐mutated colorectal cancer cells. Herein, we report a novel tankyrase‐specific inhibitor RK‐287107, which inhibits tankyrase‐1 and ‐2 four‐ and eight‐fold more potently, respectively, than G007‐LK, a tankyrase inhibitor that has been previously reported as effective in mouse xenograft models. RK‐287107 causes Axin2 accumulation and downregulates β‐catenin, T‐cell factor/lymphoid enhancer factor reporter activity and the target gene expression in colorectal cancer cells harboring the shortly truncated APC mutations. Consistently, RK‐287107 inhibits the growth of APC‐mutated (β‐catenin‐dependent) colorectal cancer COLO‐320 DM and SW 403 cells but not the APC‐wild (β‐catenin‐independent) colorectal cancer RKO cells. Intraperitoneal or oral administration of RK‐287107 suppresses COLO‐320 DM tumor growth in NOD‐SCID mice. Rates of tumor growth inhibition showed good correlation with the behavior of pharmacodynamic biomarkers, such as Axin2 accumulation and MYC downregulation. These observations indicate that RK‐287107 exerts a proof‐of‐concept antitumor effect, and thus may have potential for tankyrase‐directed molecular cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
APC, Signal transduction and genetic instability in colorectal cancer
Fodde, R., Smits, R., & Clevers, H. (2001) · Nature Reviews Cancer · doi:10.1038/35094067 · Cited by 937 · cited 1×
“(i) (1) TFA, CHCl3, reflux, 3 h; (2) NaBH(OAc)3, CHCl3- MeOH, rt, 1 h; (3) TFA, reflux, 3 h; (ii) (1) 1Amidinopyrazole hydrochloride, Et3N, CHCl3, rt, 1 h; (2) Ethyl 2- cyclohexanonecarboxylate, EtONa, EtOH, reflux, 3 h [(i) + (ii), 64% from aldehyde]; (iii) Glycolaldehyde dimer, NaBH(OAc)3, CHCl3AcOH, rt, 14 h (53%)”
Wnt Signaling through Inhibition of β-Catenin Degradation in an Intact Axin1 Complex
Li, V. S. W., Ng, S. S., Boersema, P. J., Low, T. Y., Karthaus, W. R., Gerlach, J. P., Mohammed, S., Heck, A. J. R., Maurice, M. M., Mahmoudi, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.002 · Cited by 889
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“It could down-regulate the Wnt/β-catenin signaling in Apc-truncated CRC cells, but had little effects in wild-type cancer cells.(350) An SMI from the synthetic chemical library of lycorine derivatives, 4-ethyl-5-methyl-5,6dihydro-[1,3]dioxolo[4,5-j]phenanthridine (HLY78), activated Wnt/ β-catenin signaling by targetin…”
BackgroundWnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Jung, Y.-S., & Park, J.-I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0380-6 · Cited by 419
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
β-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
Metadata
- Authors
- Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., & Seimiya, H.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2018-10-20
- Volume
- 109
- Issue
- 12
- Pages
- 4003-4014
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2890709794
- Cited by
- 80
- References
- 4
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.